Benzinga Pro's 5 Stocks To Watch Today

Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!

Pfizer Inc. PFE stock was trading slightly higher by 0.4 percent early Wednesday morning after the global pharmaceutical giant announced top-line results from a phase 3 study. The company said the trial of its Tanezumab for the treatment of osteoarthritis pain met all three co-primary endpoints.

Morgan Stanley MS gained nearly 3 percent after reporting its second-quarter results. The banking giant said it earned $1.30 per share in the second quarter on revenue of $10.6 billion versus expectations of $1.11 per share and $10.1 billion.

Catalyst Biosciences Inc CBIO was trading higher by 8 percent although the stock was seen earlier higher by more than 35 percent after reporting encouraging clinical data. The clinical-stage biopharmaceutical company reported positive interim data from a phase 2/3 study of its marzeptacog therapy supports the goal of significantly reducing annualized bleed rates with daily subcutaneous injections of marzeptacog alfa.

Adaptimmune Therapeutics PLC - ADR ADAP gained more than 3 percent after reporting an encouraging update from a study. The T-cell therapy that focuses on treating cancer announced favorable review of safety data from the second dose cohort of patients who received the company's SPEAR T-cells.

Precipio Inc PRPO spiked more than 65 percent after announcing preliminary second-quarter results. The specialty cancer diagnostics company said on a preliminary basis second quarter revenue rose 213 percent from $260,000 a year ago to $815,000.

Related Links:

28 Stocks Moving In Wednesday's Pre-Market Session

A Peek Into The Markets: US Stock Futures Flat; Morgan Stanley Earnings In Focus

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPre-Market OutlookTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...